Press Releases

Nov 6, 2019

New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders

*Oncology: New data from investigational isatuximab pivotal study for the treatment of relapsed/refractory multiple myeloma
Nov 6, 2019

New data for isatuximab in multiple myeloma to be presented at ASH 2019
Nov 4, 2019

FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

* Will be available in fall 2020, in time for the 2020-2021 flu season
Nov 4, 2019

Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes
Oct 31, 2019

Sanofi Q3 well on track
- Video 1
- Photos 4
Oct 18, 2019

Sanofi to conduct precautionary voluntary recall of Zantac OTC in U.S. and Canada
Oct 15, 2019

Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing

- One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology
- Video 1
- Photos 6
Oct 9, 2019

Innovative treatment Cablivi (caplacizumab-yhdp) granted new technology payment (NTAP) for Medicare payment

Add-on payment to provide additional Medicare reimbursement for Medicare patients prescribed Cablivi in eligible hospital inpatient settings
Sep 30, 2019

New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer

- CARD is a treatment sequencing trial investigating the efficacy and safety of Jevtana versus abiraterone or enzalutamide after disease progression following initial androgen receptor-targeted agent therapy and docetaxel
Sep 20, 2019

The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Show per page

Print
Email page
RSS